ESMO/LinkedIn
Jun 27, 2025, 13:42
ESMO Highlights Study on Role of Molecular Profiling in Endometrial Cancer Risk Stratification and Treatment
ESMO shared a post on LinkedIn:
“Molecular classification plays a pivotal role in the prognostication and management of Endometrial Cancer.
A study presented at ESMOGynae25 evaluated molecular subtyping using IHC alone versus IHC + NGS, to assess the impact of molecular reclassification on risk stratification and treatment.
Researchers concluded that comprehensive profiling identified potential targetable alterations that could influence therapy.
The findings highlight the need for advanced molecular diagnostics and updated guidelines to personalise treatment.
As we mark Uterine Cancer Awareness month, it is essential to support innovation, equity, and early detection in endometrial cancer care.”
More posts featuring ESMOGynae25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 27, 2025, 13:37